Seres Therapeutics (MCRB) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report released on Friday morning, BidAskClub reports.

Other equities research analysts also recently issued reports about the stock. Oppenheimer reissued a buy rating on shares of Seres Therapeutics in a research report on Tuesday, March 19th. HC Wainwright reissued a buy rating on shares of Seres Therapeutics in a research report on Friday, February 22nd. Cowen reissued a buy rating on shares of Seres Therapeutics in a research report on Friday, February 8th. Zacks Investment Research raised shares of Seres Therapeutics from a hold rating to a buy rating and set a $6.25 price objective on the stock in a research report on Thursday, January 10th. Finally, ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a report on Wednesday, March 27th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $13.06.

Shares of NASDAQ:MCRB opened at $6.92 on Friday. Seres Therapeutics has a 52 week low of $4.42 and a 52 week high of $9.75. The company has a market capitalization of $282.01 million, a price-to-earnings ratio of -2.85 and a beta of 1.85.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.15. Seres Therapeutics had a negative net margin of 350.03% and a negative return on equity of 1,584.13%. The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $3.78 million. As a group, equities research analysts anticipate that Seres Therapeutics will post -1.79 earnings per share for the current year.

In other news, insider Eric D. Shaff sold 4,378 shares of the company’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total value of $25,173.50. Following the completion of the transaction, the insider now owns 17,220 shares in the company, valued at approximately $99,015. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Thomas Desrosier sold 5,471 shares of the company’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total transaction of $31,458.25. Following the completion of the transaction, the executive vice president now owns 21,525 shares of the company’s stock, valued at approximately $123,768.75. The disclosure for this sale can be found here. Corporate insiders own 37.10% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Seres Therapeutics by 0.4% in the 3rd quarter. FMR LLC now owns 6,119,349 shares of the biotechnology company’s stock valued at $46,446,000 after buying an additional 23,749 shares in the last quarter. BlackRock Inc. boosted its stake in Seres Therapeutics by 1.8% during the 3rd quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock worth $17,318,000 after purchasing an additional 40,719 shares during the period. Renaissance Technologies LLC boosted its stake in Seres Therapeutics by 3.4% during the 3rd quarter. Renaissance Technologies LLC now owns 756,608 shares of the biotechnology company’s stock worth $5,743,000 after purchasing an additional 24,708 shares during the period. JPMorgan Chase & Co. boosted its stake in Seres Therapeutics by 6.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after purchasing an additional 25,287 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its stake in Seres Therapeutics by 5.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 307,930 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 17,194 shares during the period. Institutional investors and hedge funds own 77.26% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: What is channel trading?

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.